Patients for whom treatment w/ both amlodipine & atorvastatin is appropriate. Amlodipine: HTN; CAD eg, chronic stable & vasospastic angina (Prinzmetal's or variant angina) & angiographically documented CAD. Atorvastatin: To reduce risk of MI, stroke & revascularization procedures & angina in adults w/o clinically evident CHD but w/ multiple risk factors eg, age, smoking, HTN, low HDLC or family history of early CHD. To reduce risk of MI & stroke in patients w/ type 2 diabetes & w/o clinically evident CHD but w/ multiple risk factors eg, retinopathy, albuminuria, smoking or HTN. To reduce risk of non-fatal MI, fatal & non-fatal stroke, revascularization procedures, hospitalization for CHF & angina in patients w/ clinically evident CHD. Adjunct to trial of diet to reduce elevated total-C, LDL-C, apo B & TG levels & to increase HDL-C in patients w/ primary hypercholesterolemia (heterozygous familial & nonfamilial) & mixed dyslipidemia (Fredrickson types IIa & IIb). Adjunct to diet in patients w/ elevated serum TG levels (Fredrickson type IV). Patients w/ primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet. Adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable to reduce total-C & LDL-C in patients w/ HoFH. Adjunct to diet to reduce total-C, LDL-C, & apo B levels in boys & postmenarchal girls 10-17 yr w/ heterozygous familial hypercholesterolemia if after adequate diet the following findings are present: LDL-C ≥190 mg/dL or 160 mg/dL & +ve family history of premature CV disease or ≥2 other CVD risk factors are present.
Sign Out
